Chemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitors
In advanced melanoma patients after failure of immune-checkpoint inhibitors with or without BRAF/MEK inhibitors, the choice of chemotherapy regimen remains dependent on the patient's general condition, comorbidities, the need for rapid reduction of tumor masses, and physician and patient preference.
Authors
- Jacek Mackiewicz (ORCID: https://orcid.org/0000-0002-0177-2972)
- Justyna Żubrowska (ORCID: https://orcid.org/0000-0002-7876-2537)
- Daria Tusień Małecka
- Marcin Ziętek (ORCID: https://orcid.org/0000-0002-7890-3483)
- Katarzyna Kozak (ORCID: https://orcid.org/0000-0002-3225-422X)
- Brittany M. Stopa (ORCID: https://orcid.org/0000-0003-2511-5931)
- Sylwia Kopeć
- Michał Michalak (ORCID: https://orcid.org/0000-0002-2852-3984)
- Karolina Piejko (ORCID: https://orcid.org/0000-0002-0256-9220)
- Łukasz Galus (ORCID: https://orcid.org/0000-0002-9515-1834)
- Zbyszko Chowaniec
- Piotr Rutkowski (ORCID: https://orcid.org/0000-0002-8920-5429)
- Robert Dziura (ORCID: https://orcid.org/0000-0001-6177-6695)
- Wiesław Bal (ORCID: https://orcid.org/0000-0002-5810-1811)
- Grażyna Kamińska Winciorek
Institutions
- Wrocław University of Science and Technology (PL)
- Poznan University of Medical Sciences (PL)
- Wroclaw Medical University (PL)
- Greater Poland Cancer Center (PL)
- National Institute of Oncology (HU)
- Holy Cross University (PL)
- AGH University of Krakow (PL)
Publication Details
- Journal
- Współczesna Onkologia
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5114/wo.2025.150451
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00